Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$66.44M+9.2%-$73.2M+6.0%-$77.84M-6.1%-$73.37M-3.4%-$70.96M-29.6%
$1.86M+17.9%$1.57M+24.2%$1.27M+4.3%$1.22M+4.1%$1.17M+1.4%
$18.99M+15.9%$16.38M+20.2%$13.63M+22.5%$11.13M+42.1%$7.83M+22.7%
-$54.78M-7.6%-$50.93M+10.0%-$56.58M+1.5%-$57.46M-2.4%-$56.1M-16.2%
$6.34M+19.7%$5.3M+33.9%$3.96M-13.9%$4.59M+38.3%$3.32M-2.2%
-$190.24M-5,373%
$4.38M-98.0%$214.87M-20.6%$270.71M+1.4%$266.88M+0.1%$266.73M+380%
$20.38M+427%
-$61.12M-8.7%-$56.22M+7.1%-$60.53M+2.5%-$62.06M-4.4%-$59.43M-15.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Beta Bionics, Inc. Common Stock generate?
Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.
What is Beta Bionics, Inc. Common Stock's free cash flow?
After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.
Where does Beta Bionics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.